Evidence-Based Outcomes in Ketamine Therapy

When a colleague asks me whether the evidence for ketamine therapy is strong enough to warrant referring their treatment-resistant patients, I appreciate the question. It reflects the kind of scientific rigor that should govern every prescribing decision. The short answer is yes, the evidence is substantial and growing. But the longer answer, the one that actually helps clinicians make informed referral decisions, requires a careful look at what the trials have shown, where the evidence is strongest, and where legitimate uncertainty remains.

The Treatment-Resistant Depression Evidence Base

The most robust body of evidence for ketamine therapy exists in treatment-resistant depression, defined as major depressive disorder that has not responded to at least two adequate antidepressant trials. This is not a small population. Approximately 30 percent of patients with MDD meet criteria for treatment resistance, representing millions of individuals for whom the standard pharmacological toolkit has proven insufficient.

The landmark trials began with Berman and colleagues in 2000, who demonstrated that a single sub-anesthetic dose of intravenous ketamine produced rapid antidepressant effects within hours. This finding was replicated and expanded by Zarate and colleagues at the National Institute of Mental Health in 2006, establishing that roughly 70 percent of treatment-resistant patients showed significant improvement within 24 hours of a single infusion, with approximately 30 percent achieving full remission.

These are remarkable numbers for a population defined by its failure to respond to conventional treatment. For context, the number needed to treat for ketamine in TRD is approximately 3 to 5, compared to 7 to 10 for SSRIs in non-resistant depression. The effect size, typically measured around 0.8 to 1.0 on the Hamilton Depression Rating Scale, is large by any standard in psychiatric pharmacology.

Subsequent meta-analyses have consolidated these findings. The 2021 Cochrane review by Dean and colleagues, covering 64 trials (including 31 of ketamine in unipolar major depression alongside esketamine and other glutamate modulators), confirmed a rapid antidepressant effect at 24 hours, with response and remission benefits exceeding placebo. Multiple-dose protocols, which more closely mirror clinical practice, show sustained improvement over several weeks with repeated treatments.

Sublingual and Oral Routes

A question I frequently receive from referring physicians concerns the route of administration. Most published trials used intravenous ketamine, but at-home therapy programs like Tovani Health prescribe sublingual formulations. Is the evidence transferable?

The pharmacological argument is straightforward. Sublingual ketamine achieves approximately 25 to 30 percent bioavailability compared to the near-complete bioavailability of IV administration. Dosing is adjusted accordingly to achieve equivalent plasma levels and clinical effect. The onset is somewhat slower, typically 15 to 30 minutes compared to the near-immediate IV effect, and the duration is modestly longer.

Clinical data supporting sublingual ketamine specifically has grown substantially in recent years. Hassan and colleagues (2022), publishing in Frontiers in Psychiatry, retrospectively analyzed outcomes from 1,101 patients receiving telemedicine-supervised at-home sublingual ketamine for treatment-resistant depression and anxiety. After three doses, roughly 48 percent showed clinically significant PHQ-9 reduction; response rates rose meaningfully with completion of the recommended six-dose course. Real-world outcome data from telehealth ketamine programs has corroborated these findings.

The practical advantages of sublingual administration, including patient comfort, privacy, cost reduction, and the elimination of clinic-based IV access, make it the preferred route for the majority of patients who do not require the immediate onset that IV provides.

Anxiety Disorders

The evidence for ketamine in anxiety disorders is less extensive than in depression but clinically meaningful and rapidly expanding. Generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder have all been studied, with the most consistent findings in patients with comorbid depression and anxiety, which represents the majority of treatment-resistant presentations.

Glue and colleagues demonstrated in 2017 that ascending doses of subcutaneous ketamine produced significant anxiolytic effects that persisted beyond the acute pharmacological window, suggesting that the mechanism involves durable neuroplastic changes rather than merely acute symptom suppression. This is consistent with the glutamate-mediated neuroplasticity model that underpins ketamine's antidepressant mechanism.

For clinicians managing patients with treatment-resistant anxiety, the key clinical takeaway is that ketamine appears to be most effective when anxiety is conceptualized as part of a broader mood-anxiety spectrum rather than as an isolated condition. Patients with prominent anhedonia, emotional numbing, and avoidance behaviors alongside their anxiety tend to show the most robust responses.

PTSD and Trauma-Related Conditions

The evidence for ketamine in post-traumatic stress disorder has advanced considerably since Feder and colleagues published their pivotal 2014 trial demonstrating significant PTSD symptom reduction following IV ketamine. The theoretical basis is compelling. PTSD is increasingly understood as a disorder of fear memory consolidation, and ketamine's effects on NMDA-mediated synaptic plasticity directly target the neural circuits involved in traumatic memory encoding and retrieval.

A 2021 multi-site trial published in the American Journal of Psychiatry confirmed that repeated ketamine infusions produced clinically significant PTSD symptom reduction, with effects persisting for several weeks beyond the treatment period. Notably, the response was not contingent on concurrent psychotherapy, although clinical consensus holds that combining ketamine with trauma-focused therapy during the neuroplasticity window maximizes therapeutic benefit.

For veterans, first responders, and other populations with high PTSD prevalence, ketamine offers a treatment pathway that can produce measurable relief within days rather than the weeks to months typically required for SSRI-based PTSD protocols. This rapid onset has particular clinical significance for patients at elevated suicide risk, where the weeks-long delay of conventional antidepressants represents a critical vulnerability window.

Durability and Maintenance

The most common and legitimate concern I hear from referring physicians is about durability. If ketamine works rapidly, how long does the effect last, and does it require indefinite treatment?

The honest answer is that ketamine's acute antidepressant effect from a single dose typically begins to wane after five to fourteen days. This is consistent across most published trials and reflects the time course of the synaptic changes ketamine initiates. However, this finding from single-dose studies does not accurately represent clinical practice, where patients receive a series of treatments followed by a maintenance protocol.

With repeated dosing across an initial course of ten or more sessions over four to eight weeks, the cumulative effect is substantially more durable. Many patients maintain their improvement with monthly or bimonthly maintenance sessions. Some achieve sustained remission that persists after treatment discontinuation, particularly when ketamine therapy is combined with psychotherapy and lifestyle modifications during the neuroplasticity window.

The clinical analogy I use with referring colleagues is antihypertensive medication. We do not consider a blood pressure medication ineffective because blood pressure rises when the medication is discontinued. Similarly, the need for maintenance ketamine sessions does not diminish the treatment's efficacy. It reflects the chronic nature of the underlying condition.

Limitations and Honest Uncertainty

Intellectual honesty requires acknowledging what we do not know. Long-term safety data beyond two to three years of regular use is limited. The optimal maintenance frequency has not been established through large-scale randomized trials. The predictors of response versus non-response are incompletely characterized, making it difficult to identify in advance which patients will benefit most.

There is also the question of publication bias. Positive trials are more likely to be published than negative ones, and industry-funded studies may overestimate effect sizes. However, the consistency of findings across independent research groups, multiple countries, and diverse patient populations provides reassurance that the observed effects are genuine.

For clinicians weighing the decision to refer a treatment-resistant patient for ketamine therapy, the evidence supports a favorable risk-benefit calculation. The response rates are higher than those achieved by switching to yet another SSRI or SNRI, the onset is dramatically faster, and the safety profile at sub-anesthetic doses is well-characterized after more than five decades of clinical use.

What This Means for Your Practice

If you are managing patients who have not responded to two or more adequate antidepressant trials, the evidence supports considering ketamine as a next-step intervention rather than continuing to cycle through medications from the same pharmacological classes.

The evidence base for ketamine therapy has reached the point where familiarity with this treatment option is not merely useful for psychiatrists. It is relevant for any clinician managing chronic mood and anxiety disorders.

Frequently Asked Questions

How strong is the clinical evidence for ketamine therapy in depression?

Substantial. Berman 2000 first demonstrated rapid antidepressant effects within hours of a single sub-anesthetic IV dose. Zarate 2006 (NIMH) replicated and expanded this: ~70% of treatment-resistant patients showed significant improvement within 24 hours, ~30% achieved full remission. The number needed to treat (NNT) for ketamine in TRD is roughly 3-5, compared to 7-10 for SSRIs in non-resistant depression. Effect sizes (~0.8-1.0 on the Hamilton Depression Rating Scale) are large by psychiatric pharmacology standards. The evidence has been replicated across multiple international trials and consolidated in the 2021 Cochrane review (Dean et al., 64 trials).

What does the evidence show for ketamine in PTSD specifically?

Promising and growing. Feder 2014 (JAMA Psychiatry) showed single-dose IV ketamine produced significant PTSD symptom reduction. Feder 2021 (American Journal of Psychiatry) extended this to a multi-dose protocol: six infusions over two weeks produced ~60% response rate, with first-session indicator typically reliable. Albott 2018 demonstrated benefit in veterans with comorbid PTSD and depression. The PTSD evidence is less mature than the TRD evidence but converges on response rates similar to or slightly lower than depression outcomes.

Does ketamine actually work faster than traditional antidepressants?

Yes, verifiably and substantially. The published literature consistently shows mood improvement within hours to days of the first ketamine dose, compared to 4-8 weeks for SSRIs and SNRIs. This isn't a minor difference; it represents a fundamentally different mechanism of action. NMDA-receptor antagonism triggers rapid synaptic plasticity (BDNF release, AMPA activation, dendritic spine growth) that doesn't require the weeks of receptor adaptation that monoamine antidepressants need. For acute clinical situations (particularly suicidal ideation) this speed difference matters significantly.

How durable are the antidepressant effects of ketamine?

Variable and dose-dependent on the protocol. Single-dose effects typically last 1-2 weeks; the value of an initial course of 10 or more sessions over 4-8 weeks is producing more durable response. After completing the course, many patients experience 4-12 weeks of stable improvement before needing maintenance. Effect duration is longest in patients who pair ketamine with active integration work (psychotherapy, lifestyle changes during the neuroplasticity window) rather than treating it as a standalone medical intervention. Maintenance protocols are individualized but typically range from monthly to every 6-8 weeks.

Sources

The studies referenced in this article, with PubMed links for verification:

1. Berman et al. 2000 — single-dose IV ketamine antidepressant effect. Biol Psychiatry. PMID: 10686270
2. Zarate et al. 2006 — RCT in TRD, 70% response at 24h. Arch Gen Psychiatry. PMID: 16894061
3. Diazgranados et al. 2010 — rapid suicidal-ideation reduction. J Clin Psychiatry. PMID: 20673547
4. Feder et al. 2014 — single-dose IV ketamine in chronic PTSD. JAMA Psychiatry. PMID: 24740528
5. Glue et al. 2017 — dose-response in treatment-refractory anxiety disorders. J Psychopharmacol. PMID: 28441895
6. Grunebaum et al. 2018 — ketamine vs midazolam suicidal-ideation trial. Am J Psychiatry. PMID: 29202655
7. Albott et al. 2018 — repeated infusions in veterans with comorbid PTSD + TRD. J Clin Psychiatry. PMID: 29727073
8. Feder et al. 2021 — multi-dose IV ketamine in chronic PTSD. Am J Psychiatry. PMID: 33397139
9. Dean et al. 2021 — Cochrane review of 64 trials (31 of ketamine in unipolar depression). Cochrane Database Syst Rev. PMID: 34510411
10. Hassan et al. 2022 — at-home sublingual ketamine, n=1,101. Front Psychiatry. PMID: 36245861

Considering ketamine therapy as a referral option for a treatment-resistant patient?

Tovani Health is a physician-led at-home ketamine therapy practice serving Florida and New Jersey. We coordinate with referring providers throughout treatment and welcome professional consultations on whether a specific patient might be a candidate. The fastest way to determine fit is our 5-minute eligibility assessment.

Refer a patient via /eligibility →

Want to discuss a case directly, or talk through the evidence as it applies to a specific patient profile? Call 561-468-6981.

Benjamin Soffer, DO — Tovani Health

---

Related professional reading: ketamine pharmacological mechanisms, SSRI vs ketamine pharmacological comparison, referral guidelines for primary care, clinical protocols and patient selection.